WPI 2357 Pill - yellow capsule/oblong, 16mm
Pill with imprint WPI 2357 is Yellow, Capsule/Oblong and has been identified as Topiramate Extended-Release 50 mg. It is supplied by Teva Pharmaceuticals USA, Inc.
Topiramate is used in the treatment of Migraine Prevention; Lennox-Gastaut Syndrome; Seizure Prevention; Epilepsy; Seizures and belongs to the drug class carbonic anhydrase inhibitor anticonvulsants. There is positive evidence of human fetal risk during pregnancy. Topiramate 50 mg is not a controlled substance under the Controlled Substances Act (CSA).
Images for WPI 2357
Topiramate Extended-Release
- Imprint
- WPI 2357
- Strength
- 50 mg
- Color
- Yellow
- Size
- 16.00 mm
- Shape
- Capsule/Oblong
- Availability
- Prescription only
- Drug Class
- Carbonic anhydrase inhibitor anticonvulsants
- Pregnancy Category
- D - Positive evidence of risk
- CSA Schedule
- Not a controlled drug
- Labeler / Supplier
- Teva Pharmaceuticals USA, Inc.
- National Drug Code (NDC)
- 00480-2357
More about topiramate
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (1,327)
- Drug images
- Side effects
- Dosage information
- Patient tips
- During pregnancy
- Support group
- Drug class: carbonic anhydrase inhibitor anticonvulsants
- Breastfeeding
Patient resources
- Topiramate drug information
- Topiramate Extended-Release Capsules
- Topiramate Extended-Release Sprinkle Capsules
- Topiramate Sprinkle Capsules
Other brands
Topamax, Trokendi XR, Eprontia, Topiragen, Qudexy XR
Professional resources
- Topiramate monograph
- Topiramate (FDA)
- Topiramate Capsules (FDA)
- Topiramate ER Capsules (FDA)
- Topiramate Tablets (FDA)
Other brands
Topamax, Trokendi XR, Eprontia, Qudexy XR
Related treatment guides
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.